


Certificate of Analysis

Catalog Number	BP22333
Product Name	VS-5584

Physical and Chemical Properties

Synonyms	VS5584, VS 5584, SB2343
CAS No.	1246560-33-7
Chemical Formula	C ₁₇ H ₂₂ N ₈ O
Molecular Weight	354.418
Solubility	Ethanol: 3 mg/mL (8.46 mM) DMSO: 66 mg/mL (186.2 mM); H ₂ O: <1 mg/mL
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	 <p>The chemical structure of VS-5584 is a complex molecule featuring a central pyrimidine ring. This central ring is substituted with a 4-aminophenyl group at the 2-position, a 4-methyl-1H-imidazol-2-yl group at the 6-position, and a 4-morpholinyl group at the 4-position. The morpholine ring is attached via its nitrogen atom to the 4-position of the central pyrimidine ring.</p>

Product Information

Description	VS-5584 is a pan-PI3K/mTOR kinase inhibitor.
-------------	--

Targets&IC50	mTOR:3.4 nM, PI3K γ :3.0 nM, PI3K α :2.6 nM, PI3K β :21 nM, PI3K δ :2.7 nM
In vitro	VS-5584 is an ATP-competitive inhibitor which selectively inhibits PI3K/mTOR signaling with equivalent low nanomolar potency against all human Class I PI3K isoforms and mTOR kinase. VS-5584 is approximately 10-fold selective for cancer stem cells with an EC50 of 15 nM in HMLE breast cancer cells. VS-5584 preferentially decreases CD44 ^{Hi} /CD24 ^{Lo} cells in an HMLER immortalized mammary cancer cell line. In SUM159 cells, VS-5584 effectively eliminates the cancer stem cell side population. A large human cancer cell line panel screen (436 lines) reveals broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment. In the FLT3-ITD harboring MV4-11 cells, VS-5584 blocks pAkt (S473) and pAkt (T308) with IC50 of 12 and 13 nM, respectively. The IC50 of VS-5584 for pS6 (S240/244), pAkt (S473), and pAkt (T308) are 20, 23, and 15 nM, respectively.
In vivo	In mice bearing triple negative breast cancer tumors, oral dosing of VS-5584 decreases tumor cancer stem cells and induces tumor regression in taxane-resistant models. In a PTENnull human prostate PC3 xenograft model, treatment with VS-5584 leads to significant tumor growth inhibition (TGI) of 79% and 113% for 11 and 25 mg/kg, respectively. In a FLT3-ITD AML xenograft model, VS-5584 treatment induces dose-dependent inhibition of tumor growth (28% for 3.7 mg/kg and 76% for 11 mg/kg).

Analytical Data

HPLC	Shows Min >99% purity
H-NMR	Consistent with structure
Stability and Solubility Advice	Information on product stability, especially in solution, has rarely been reported and in most cases we can only provide a general guideline. We recommend that once the stock solution has been prepared, it be stored in equal quantities in sealed vials and used within 1 month. Avoid repeated freezing and thawing cycles. Storage conditions for some special products should be referred to their storage details.

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<http://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022

Purdue Bioscience Inc.